In addition, most of the innovation in the glucagon field was focused on developing novel glucagon receptor antagonists for the treatment of T2D, due to the impact of glucagon on hepatic glucose production and hyperglycemia (149–151). The gene discussed is GCGR; the disease is type 2 diabetes mellitus.